Top

Published in:

01-08-2015 | Review Article

Emotional Lability in Patients with Attention-Deficit/Hyperactivity Disorder: Impact of Pharmacotherapy

Authors: Ann C. Childress, Floyd R. Sallee

Published in: CNS Drugs | Issue 8/2015

Abstract

Attention-deficit/hyperactivity disorder (ADHD) is a neurobehavioral disorder defined by persistent inattention and/or hyperactivity and impulsivity. These symptoms occur more frequently and are more severe in individuals with ADHD compared with those at a similar developmental level without ADHD, and can be conceptualized as deficits in executive functioning (EF). EF includes domains of metacognition and inhibition, which influence the ability to regulate responses elicited by emotional stimuli. EF deficits can lead to emotional lability (EL), which is characterized by sudden changes in emotion and behaviors of inappropriately high intensity that may include sudden bouts of anger, dysphoria, sadness, or euphoria. EL is common and estimated to occur in about 3.3–10 % of the population. Recent estimates of EL prevalence in children and adolescents with ADHD range from 38 to 75 %. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition does not include EL in diagnostic criteria for ADHD, but does include ADHD-associated features of low frustration tolerance, irritability, or mood lability. The neurobiological basis of EL is not well understood, but brain imaging studies support dividing EF into “cool” cognitive networks encompassing attention and planning activities, and “hot” motivational networks involved in temporal discounting, reward processing, and reward anticipation. Dysfunction in “hot” networks is thought to be related to EL. EL symptoms are associated with more severe ADHD and co-morbidities, have significant impact on functioning, and may respond to treatment with medications frequently used to treat ADHD. Treatment outcomes and areas for future research are discussed.

American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Association; 2013.

Increasing prevalence of parent-reported attention-deficit/hyperactivity disorder among children: United States, 2003 and 2007. MMWR Morb Mortal Wkly Rep. 2010;59(44):1439–43 (pii: mm5944a3).

Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164(6):942–8. doi:10.1176/appi.ajp.164.6.942.CrossRefPubMed

Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716–23. doi:10.1176/appi.ajp.163.4.716.PubMedCentralCrossRefPubMed

Simon V, Czobor P, Balint S, Meszaros A, Bitter I. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry. 2009;194(3):204–11. doi:10.1192/bjp.bp.107.048827.CrossRefPubMed

Asherson P, Chen W, Craddock B, Taylor E. Adult attention-deficit hyperactivity disorder: recognition and treatment in general adult psychiatry. Br J Psychiatry. 2007;190:4–5. doi:10.1192/bjp.bp.106.026484.CrossRefPubMed

Barkley RA, Fischer M. The unique contribution of emotional impulsiveness to impairment in major life activities in hyperactive children as adults. J Am Acad Child Adolesc Psychiatry. 2010;49(5):503–13 (pii: 00004583-201005000-00011).PubMed

Leibenluft E, Blair RJ, Charney DS, Pine DS. Irritability in pediatric mania and other childhood psychopathology. Ann N Y Acad Sci. 2003;1008:201–18.CrossRefPubMed

Leibenluft E, Cohen P, Gorrindo T, Brook JS, Pine DS. Chronic versus episodic irritability in youth: a community-based, longitudinal study of clinical and diagnostic associations. J Child Adolesc Psychopharmacol. 2006;16(4):456–66. doi:10.1089/cap.2006.16.456.CrossRefPubMed

10.

Brotman MA, Schmajuk M, Rich BA, Dickstein DP, Guyer AE, Costello EJ, et al. Prevalence, clinical correlates, and longitudinal course of severe mood dysregulation in children. Biol Psychiatry. 2006;60(9):991–7. doi:10.1016/j.biopsych.2006.08.042.CrossRefPubMed

11.

Sobanski E, Banaschewski T, Asherson P, Buitelaar J, Chen W, Franke B, et al. Emotional lability in children and adolescents with attention deficit/hyperactivity disorder (ADHD): clinical correlates and familial prevalence. J Child Psychol Psychiatry. 2010;51(8):915–23. doi:10.1111/j.1469-7610.2010.02217.x.CrossRefPubMed

12.

Biederman J, Spencer TJ, Petty C, Hyder LL, O’Connor KB, Surman CB, et al. Longitudinal course of deficient emotional self-regulation CBCL profile in youth with ADHD: prospective controlled study. Neuropsychiatr Dis Treat. 2012;8:267–76. doi:10.2147/NDT.S29670.PubMedCentralCrossRefPubMed

13.

Carlson GA, Kelly KL. Manic symptoms in psychiatrically hospitalized children: what do they mean? J Affect Disord. 1998;51(2):123–35 (pii: S0165-0327(98)00211-0).CrossRefPubMed

14.

Maedgen JW, Carlson CL. Social functioning and emotional regulation in the attention deficit hyperactivity disorder subtypes. J Clin Child Psychol. 2000;29(1):30–42. doi:10.1207/S15374424jccp2901_4.CrossRefPubMed

15.

Towbin K, Axelson D, Leibenluft E, Birmaher B. Differentiating bipolar disorder-not otherwise specified and severe mood dysregulation. J Am Acad Child Adolesc Psychiatry. 2013;52(5):466–81. doi:10.1016/j.jaac.2013.02.006.PubMedCentralCrossRefPubMed

16.

Barkley RA, McMurray MB, Edelbrock CS, Robbins K. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics. 1990;86(2):184–92.PubMed

17.

Stringaris A, Goodman R. Mood lability and psychopathology in youth. Psychol Med. 2009;39(8):1237–45. doi:10.1017/S0033291708004662.CrossRefPubMed

18.

Anastopoulos AD, Smith TF, Garrett ME, Morrissey-Kane E, Schatz NK, Sommer JL, et al. Self-regulation of emotion, functional impairment, and comorbidity among children with AD/HD. J Atten Disord. 2011;15(7):583–92. doi:10.1177/1087054710370567.PubMedCentralCrossRefPubMed

19.

Spencer TJ, Faraone SV, Surman CB, Petty C, Clarke A, Batchelder H, et al. Toward defining deficient emotional self-regulation in children with attention-deficit/hyperactivity disorder using the Child Behavior Checklist: a controlled study. Postgrad Med. 2011;123(5):50–9. doi:10.3810/pgm.2011.09.2459.PubMedCentralCrossRefPubMed

20.

Donfrancesco R, Innocenzi M, Marano A, Biederman J. Deficient emotional self-regulation in ADHD assessed using a unique profile of the Child Behavior Checklist (CBCL): replication in an Italian study. J Atten Disord. 2012;. doi:10.1177/1087054712462884.

21.

Reimherr FW, Marchant BK, Strong RE, Hedges DW, Adler L, Spencer TJ, et al. Emotional dysregulation in adult ADHD and response to atomoxetine. Biol Psychiatry. 2005;58(2):125–31. doi:10.1016/j.biopsych.2005.04.040.CrossRefPubMed

22.

Wender PH, Reimherr FW, Wood DR. Attention deficit disorder (‘minimal brain dysfunction’) in adults: a replication study of diagnosis and drug treatment. Arch Gen Psychiatry. 1981;38(4):449–56.CrossRefPubMed

23.

Ward MF, Wender PH, Reimherr FW. The Wender Utah Rating Scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder. Am J Psychiatry. 1993;150(6):885–90.CrossRefPubMed

24.

Vidal R, Valero S, Nogueira M, Palomar G, Corrales M, Richarte V, et al. Emotional lability: the discriminative value in the diagnosis of attention deficit/hyperactivity disorder in adults. Compr Psychiatry. 2014;55(7):1712–9. doi:10.1016/j.comppsych.2014.07.001.CrossRefPubMed

25.

Skirrow C, Asherson P. Emotional lability, comorbidity and impairment in adults with attention-deficit hyperactivity disorder. J Affect Disord. 2013;147(1–3):80–6. doi:10.1016/j.jad.2012.10.011.CrossRefPubMed

26.

Reimherr FW, Williams ED, Strong RE, Mestas R, Soni P, Marchant BK. A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. J Clin Psychiatry. 2007;68(1):93–101.CrossRefPubMed

27.

Marchant BK, Reimherr FW, Robison D, Robison RJ, Wender PH. Psychometric properties of the Wender-Reimherr Adult Attention Deficit Disorder Scale. Psychol Assess. 2013;25(3):942–50. doi:10.1037/a0032797.CrossRefPubMed

28.

Surman CB, Biederman J, Spencer T, Miller CA, McDermott KM, Faraone SV. Understanding deficient emotional self-regulation in adults with attention deficit hyperactivity disorder: a controlled study. Atten Defic Hyperact Disord. 2013;5(3):273–81. doi:10.1007/s12402-012-0100-8.PubMedCentralCrossRefPubMed

29.

Barkley RA, Murphy K. Deficient emotional self-regulation in adults with attention-deficit/hyperactivity disorder (ADHD): the relative contributions of emotional impulsiveness and ADHD symptoms to adaptive impairments in major life activities. J ADHD Relat Disord. 2010;1(4):5–28.

30.

Chan RC, Shum D, Toulopoulou T, Chen EY. Assessment of executive functions: review of instruments and identification of critical issues. Arch Clin Neuropsychol. 2008;23(2):201–16. doi:10.1016/j.acn.2007.08.010.CrossRefPubMed

31.

Arnsten AF, Rubia K. Neurobiological circuits regulating attention, cognitive control, motivation, and emotion: disruptions in neurodevelopmental psychiatric disorders. J Am Acad Child Adolesc Psychiatry. 2012;51(4):356–67. doi:10.1016/j.jaac.2012.01.008.CrossRefPubMed

32.

Cubillo A, Halari R, Smith A, Taylor E, Rubia K. A review of fronto-striatal and fronto-cortical brain abnormalities in children and adults with attention deficit hyperactivity disorder (ADHD) and new evidence for dysfunction in adults with ADHD during motivation and attention. Cortex. 2012;48(2):194–215. doi:10.1016/j.cortex.2011.04.007.CrossRefPubMed

33.

Barkley RA. Differential diagnosis of adults with ADHD: the role of executive function and self-regulation. J Clin Psychiatry. 2010;71(7):e17. doi:10.4088/JCP.9066tx1c.CrossRefPubMed

34.

Barkley RA. Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. Psychol Bull. 1997;121(1):65–94.CrossRefPubMed

35.

Posner J, Kass E, Hulvershorn L. Using stimulants to treat ADHD-related emotional lability. Curr Psychiatry Rep. 2014;16(10):478. doi:10.1007/s11920-014-0478-4.CrossRefPubMed

36.

Finger EC, Marsh AA, Mitchell DG, Reid ME, Sims C, Budhani S, et al. Abnormal ventromedial prefrontal cortex function in children with psychopathic traits during reversal learning. Arch Gen Psychiatry. 2008;65(5):586–94. doi:10.1001/archpsyc.65.5.586.PubMedCentralCrossRefPubMed

37.

Shaw P, Stringaris A, Nigg J, Leibenluft E. Emotion dysregulation in attention deficit hyperactivity disorder. Am J Psychiatry. 2014;171(3):276–93. doi:10.1176/appi.ajp.2013.13070966.PubMedCentralCrossRefPubMed

38.

Passarotti AM, Sweeney JA, Pavuluri MN. Emotion processing influences working memory circuits in pediatric bipolar disorder and attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2010;49(10):1064–80. doi:10.1016/j.jaac.2010.07.009.PubMedCentralCrossRefPubMed

39.

Herpertz SC, Huebner T, Marx I, Vloet TD, Fink GR, Stoecker T, et al. Emotional processing in male adolescents with childhood-onset conduct disorder. J Child Psychol Psychiatry. 2008;49(7):781–91. doi:10.1111/j.1469-7610.2008.01905.x.CrossRefPubMed

40.

Frodl T, Stauber J, Schaaff N, Koutsouleris N, Scheuerecker J, Ewers M, et al. Amygdala reduction in patients with ADHD compared with major depression and healthy volunteers. Acta Psychiatr Scand. 2010;121(2):111–8. doi:10.1111/j.1600-0447.2009.01489.x.CrossRefPubMed

41.

Brotman MA, Rich BA, Guyer AE, Lunsford JR, Horsey SE, Reising MM, et al. Amygdala activation during emotion processing of neutral faces in children with severe mood dysregulation versus ADHD or bipolar disorder. Am J Psychiatry. 2010;167(1):61–9. doi:10.1176/appi.ajp.2009.09010043.PubMedCentralCrossRefPubMed

42.

Posner J, Nagel BJ, Maia TV, Mechling A, Oh M, Wang Z, et al. Abnormal amygdalar activation and connectivity in adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011;50(8):828–37. doi:10.1016/j.jaac.2011.05.010 (e3).PubMedCentralCrossRefPubMed

43.

Malisza KL, Clancy C, Shiloff D, Holden J, Jones C, Paulson K, et al. Functional magnetic resonance imaging of facial information processing in children with autistic disorder, attention deficit hyperactivity disorder and typically developing controls. Int J Adolesc Med Health. 2011;23(3):269–77.PubMed

44.

Sterzer P, Stadler C, Krebs A, Kleinschmidt A, Poustka F. Abnormal neural responses to emotional visual stimuli in adolescents with conduct disorder. Biol Psychiatry. 2005;57(1):7–15. doi:10.1016/j.biopsych.2004.10.008.CrossRefPubMed

45.

Marsh R, Gerber AJ, Peterson BS. Neuroimaging studies of normal brain development and their relevance for understanding childhood neuropsychiatric disorders. J Am Acad Child Adolesc Psychiatry. 2008;47(11):1233–51. doi:10.1097/CHI.0b013e318185e703.PubMedCentralCrossRefPubMed

46.

Posner J, Maia TV, Fair D, Peterson BS, Sonuga-Barke EJ, Nagel BJ. The attenuation of dysfunctional emotional processing with stimulant medication: an fMRI study of adolescents with ADHD. Psychiatry Res. 2011;193(3):151–60. doi:10.1016/j.pscychresns.2011.02.005.PubMedCentralCrossRefPubMed

47.

Hulvershorn LA, Mennes M, Castellanos FX, Di Martino A, Milham MP, Hummer TA, et al. Abnormal amygdala functional connectivity associated with emotional lability in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2014;53(3):351–61. doi:10.1016/j.jaac.2013.11.012 (e1).PubMedCentralCrossRefPubMed

48.

Rosler M, Retz W, Fischer R, Ose C, Alm B, Deckert J, et al. Twenty-four-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD. World J Biol Psychiatry. 2010;11(5):709–18. doi:10.3109/15622971003624197.CrossRefPubMed

49.

Marchant BK, Reimherr FW, Robison RJ, Olsen JL, Kondo DG. Methylphenidate transdermal system in adult ADHD and impact on emotional and oppositional symptoms. J Atten Disord. 2011;15(4):295–304. doi:10.1177/1087054710365986.CrossRefPubMed

50.

Childress AC, Arnold V, Adeyi B, Dirks B, Babcock T, Scheckner B, et al. The effects of lisdexamfetamine dimesylate on emotional lability in children 6 to 12 years of age with ADHD in a double-blind placebo-controlled trial. J Atten Disord. 2014;18(2):123–32. doi:10.1177/1087054712448252.CrossRefPubMed

51.

Kumar G, Steer RA. Factorial validity of the Conners’ Parent Rating Scale-revised: short form with psychiatric outpatients. J Pers Assess. 2003;80(3):252–9. doi:10.1207/S15327752JPA8003_04.CrossRefPubMed

52.

Findling RL, Ginsberg LD, Jain R, Gao J. Effectiveness, safety, and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: an open-label, dose-optimization study. J Child Adolesc Psychopharmacol. 2009;19(6):649–62. doi:10.1089/cap.2008.0165.CrossRefPubMed

53.

Katic A, Ginsberg L, Jain R, Adeyi B, Dirks B, Babcock T, et al. Clinically relevant changes in emotional expression in children with ADHD treated with lisdexamfetamine dimesylate. J Atten Disord. 2012;16(5):384–97. doi:10.1177/1087054710389990.CrossRefPubMed

54.

Gioia GA, Isquith PK, Guy SC, Kenworthy L. Behavior rating inventory of executive function. Child Neuropsychol. 2000;6(3):235–8. doi:10.1076/chin.6.3.235.3152.CrossRefPubMed

55.

Perwien AR, Kratochvil CJ, Faries D, Vaughan B, Busner J, Saylor KE, et al. Emotional expression in children treated with ADHD medication: development of a new measure. J Atten Disord. 2008;11(5):568–79. doi:10.1177/1087054707306117.CrossRefPubMed

56.

Potter AS, Dunbar G, Mazzulla E, Hosford D, Newhouse PA. AZD3480, a novel nicotinic receptor agonist, for the treatment of attention-deficit/hyperactivity disorder in adults. Biol Psychiatry. 2014;75(3):207–14. doi:10.1016/j.biopsych.2013.06.002.CrossRefPubMed

57.

Wood DR, Reimherr FW, Wender PH, Johnson GE. Diagnosis and treatment of minimal brain dysfunction in adults: a preliminary report. Arch Gen Psychiatry. 1976;33(12):1453–60.CrossRefPubMed

58.

Bangs ME, Emslie GJ, Spencer TJ, Ramsey JL, Carlson C, Bartky EJ, et al. Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression. J Child Adolesc Psychopharmacol. 2007;17(4):407–20. doi:10.1089/cap.2007.0066.CrossRefPubMed

59.

Corp SA, Gitlin MJ, Altshuler LL. A review of the use of stimulants and stimulant alternatives in treating bipolar depression and major depressive disorder. J Clin Psychiatry. 2014;75(9):1010–8. doi:10.4088/JCP.13r08851.CrossRefPubMed

60.

Shire. Shire reports top-line results from two phase 3 studies for Vyanse^® (lisdexamfetamine dimesylate) capsules (CII) as an adjunctive treatment for adults with major depressive disorder. http://www.shire.com/shireplc/en/investors/irshirenews?id=921. Accessed 25 Feb 2015.

61.

Schulz KP, Clerkin SM, Newcorn JH, Halperin JM, Fan J. Guanfacine modulates the emotional biasing of amygdala-prefrontal connectivity for cognitive control. Eur Neuropsychopharmacol. 2014;24(9):1444–53. doi:10.1016/j.euroneuro.2014.06.016.PubMedCentralCrossRefPubMed

62.

Conners CK, Sitarenios G, Parker JD, Epstein JN. The revised Conners’ Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol. 1998;26(4):257–68.CrossRefPubMed

63.

Erhardt D, Epstein JN, Conners CK, Parker JA, Sitarenios G. Self-ratings of ADHD symptoms in adults II: reliability, validity, and diagnostic sensitivity. J Atten Disord. 1999;3:153–8.CrossRef

Title: Emotional Lability in Patients with Attention-Deficit/Hyperactivity Disorder: Impact of Pharmacotherapy
Authors: Ann C. Childress
Floyd R. Sallee
Publication date: 01-08-2015
Publisher: Springer International Publishing
Published in: CNS Drugs / Issue 8/2015
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI: https://doi.org/10.1007/s40263-015-0264-9

At a glance: The STEP trials

Springer Medicine

Emotional Lability in Patients with Attention-Deficit/Hyperactivity Disorder: Impact of Pharmacotherapy

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2015

Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants

Modified-Release Formulations of Second-Generation Antiepileptic Drugs: Pharmacokinetic and Clinical Aspects

Intravenous Recombinant Tissue Plasminogen Activator Does Not Impact Mortality in Acute Ischemic Stroke at Any Time Point up to 6 Months: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials

Erratum to: Oxycodone/Naloxone PR: A Review in Severe Refractory Restless Legs Syndrome

Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer’s Disease

The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics